MorphoSys AG (WBO:MOR)
€ 67.6 0.8 (1.2%) Market Cap: 2.53 Bil Enterprise Value: 2.49 Bil PE Ratio: 0 PB Ratio: 52.00 GF Score: 59/100

MorphoSys AG at UBS Global Healthcare Virtual Conference Transcript

May 25, 2021 / 11:00AM GMT
Release Date Price: €71.32 (+0.51%)
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

Hi, everyone. I'm Ellie Merle. I'm one of the biotech analysts here at UBS. Thank you very much for joining us at the UBS Healthcare Conference. Very happy to have MorphoSys here with us today. With us from MorphoSys is Jean-Paul Kress, CEO. We'll be doing a fireside chat format today. And with that, I'll turn it over to you, Jean-Paul. Maybe high level, you can -- for those less familiar with the story, give us some background on MorphoSys, your antibody capabilities? And kind of high-level what your key goals are over the coming years.

Jean;Paul Kress
MorphoSys AG - Chairman of Management Board, MD & CEO

Thanks, Ellie. And thanks for having me. Hi, everyone. Sure. So MorphoSys has been for several years, a leader in antibody discovery, engineering and development. We have established HQs many years ago in Germany, close to Munich, and we've recently expanded in the United States to launch our first proprietary asset, tafasitamab or Monjuvi, I'm sure we'll talk about

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot